

Special Issue

Deuterium Depletion: From Basic Research to Novel Therapeutic Approaches

Message from the Guest Editor

This Special Issue will mainly focus on the role of deuterium and/or the deuterium/hydrogen ratio in the regulation of cell cycle, cell metabolism and about the therapeutic efficacy of deuterium depletion in a wide range of indications. The issue will focus on deuterium depletion as a new drug development strategy and its clinical implementation. Submissions proving the efficacy of deuterium depletion in other indications will also fit the scope of the Special Issue. Deuterium depletion is an emerging field of research. In *recent years, the number of publications* examining the effects of deuterium-depleted water (DDW) in different biological systems has increased across a wide array of fields, including cancer and metabolic disease research, depression, cognitive functions, and aging. The Special Issue of *Biomedicines* is a collection of papers centered around the basic and clinical research of deuterium depletion organized and led by subject experts. We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Guest Editor

Dr. Gábor Somlyai

HYD LLC for Cancer Research and Drug Development, 1118 Budapest, Hungary

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/165727

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).